Minireview: Alternative activation pathways for the androgen receptor in prostate cancer

Kristin R. Lamont, Donald J. Tindall

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

Advanced prostate tumors, which are androgen dependent, are often initially treated in the clinic with hormone ablation therapy, either through surgical castration or administration of small-molecule antiandrogens. Most tumors respond favorably to these treatments, exhibiting regression of the tumor, amelioration of symptoms, and a decrease of prostate-specific antigen in patient sera. However, with time, the majority of tumors recur in a more aggressive, castration-resistant (CR) phenotype. Currently, no effective treatment exists for this stage of the cancer, and patients ultimately succumb to metastatic disease. The androgen receptor (AR), which is a member of the nuclear hormone receptor superfamily of proteins, is the transcription factor that is responsible for mediating the effects of androgens upon target tissues, and it has been demonstrated to play a central role in the development and progression of prostate cancer. Despite CR tumor cells being able to continue to grow after hormonal therapy in which testosterone and dihydrotestosterone are markedly reduced, they still require the expression and activity of the AR. The AR can become transactivated in this low-androgen environment through a number of different mechanisms, including amplification and mutation of the receptor, cross talk with other signaling pathways, and altered regulation by coregulatory proteins. This review will summarizethe most current data regarding non-ligand-mediated activation of the AR in prostate cancer cells. Developing work in this field aims to more clearly elucidate the signals that drive AR activity independently of androgens in CR disease so that better therapeutic targets can be developed for patients with this stage of highly aggressive prostate carcinoma. (Molecular Endocrinology 25: 897-907, 2011).

Original languageEnglish (US)
Pages (from-to)897-907
Number of pages11
JournalMolecular Endocrinology
Volume25
Issue number6
DOIs
StatePublished - Jun 2011

Fingerprint

Androgen Receptors
Prostatic Neoplasms
Castration
Androgens
Neoplasms
Prostate
Receptor Cross-Talk
Therapeutics
Androgen Antagonists
Dihydrotestosterone
Endocrinology
Prostate-Specific Antigen
Cytoplasmic and Nuclear Receptors
Testosterone
Proteins
Transcription Factors
Hormones
Carcinoma
Phenotype
Mutation

ASJC Scopus subject areas

  • Molecular Biology
  • Endocrinology

Cite this

Minireview : Alternative activation pathways for the androgen receptor in prostate cancer. / Lamont, Kristin R.; Tindall, Donald J.

In: Molecular Endocrinology, Vol. 25, No. 6, 06.2011, p. 897-907.

Research output: Contribution to journalArticle

Lamont, Kristin R. ; Tindall, Donald J. / Minireview : Alternative activation pathways for the androgen receptor in prostate cancer. In: Molecular Endocrinology. 2011 ; Vol. 25, No. 6. pp. 897-907.
@article{d54b5903b88442c3b82cfab0bd8f652f,
title = "Minireview: Alternative activation pathways for the androgen receptor in prostate cancer",
abstract = "Advanced prostate tumors, which are androgen dependent, are often initially treated in the clinic with hormone ablation therapy, either through surgical castration or administration of small-molecule antiandrogens. Most tumors respond favorably to these treatments, exhibiting regression of the tumor, amelioration of symptoms, and a decrease of prostate-specific antigen in patient sera. However, with time, the majority of tumors recur in a more aggressive, castration-resistant (CR) phenotype. Currently, no effective treatment exists for this stage of the cancer, and patients ultimately succumb to metastatic disease. The androgen receptor (AR), which is a member of the nuclear hormone receptor superfamily of proteins, is the transcription factor that is responsible for mediating the effects of androgens upon target tissues, and it has been demonstrated to play a central role in the development and progression of prostate cancer. Despite CR tumor cells being able to continue to grow after hormonal therapy in which testosterone and dihydrotestosterone are markedly reduced, they still require the expression and activity of the AR. The AR can become transactivated in this low-androgen environment through a number of different mechanisms, including amplification and mutation of the receptor, cross talk with other signaling pathways, and altered regulation by coregulatory proteins. This review will summarizethe most current data regarding non-ligand-mediated activation of the AR in prostate cancer cells. Developing work in this field aims to more clearly elucidate the signals that drive AR activity independently of androgens in CR disease so that better therapeutic targets can be developed for patients with this stage of highly aggressive prostate carcinoma. (Molecular Endocrinology 25: 897-907, 2011).",
author = "Lamont, {Kristin R.} and Tindall, {Donald J.}",
year = "2011",
month = "6",
doi = "10.1210/me.2010-0469",
language = "English (US)",
volume = "25",
pages = "897--907",
journal = "Molecular Endocrinology",
issn = "0888-8809",
publisher = "The Endocrine Society",
number = "6",

}

TY - JOUR

T1 - Minireview

T2 - Alternative activation pathways for the androgen receptor in prostate cancer

AU - Lamont, Kristin R.

AU - Tindall, Donald J.

PY - 2011/6

Y1 - 2011/6

N2 - Advanced prostate tumors, which are androgen dependent, are often initially treated in the clinic with hormone ablation therapy, either through surgical castration or administration of small-molecule antiandrogens. Most tumors respond favorably to these treatments, exhibiting regression of the tumor, amelioration of symptoms, and a decrease of prostate-specific antigen in patient sera. However, with time, the majority of tumors recur in a more aggressive, castration-resistant (CR) phenotype. Currently, no effective treatment exists for this stage of the cancer, and patients ultimately succumb to metastatic disease. The androgen receptor (AR), which is a member of the nuclear hormone receptor superfamily of proteins, is the transcription factor that is responsible for mediating the effects of androgens upon target tissues, and it has been demonstrated to play a central role in the development and progression of prostate cancer. Despite CR tumor cells being able to continue to grow after hormonal therapy in which testosterone and dihydrotestosterone are markedly reduced, they still require the expression and activity of the AR. The AR can become transactivated in this low-androgen environment through a number of different mechanisms, including amplification and mutation of the receptor, cross talk with other signaling pathways, and altered regulation by coregulatory proteins. This review will summarizethe most current data regarding non-ligand-mediated activation of the AR in prostate cancer cells. Developing work in this field aims to more clearly elucidate the signals that drive AR activity independently of androgens in CR disease so that better therapeutic targets can be developed for patients with this stage of highly aggressive prostate carcinoma. (Molecular Endocrinology 25: 897-907, 2011).

AB - Advanced prostate tumors, which are androgen dependent, are often initially treated in the clinic with hormone ablation therapy, either through surgical castration or administration of small-molecule antiandrogens. Most tumors respond favorably to these treatments, exhibiting regression of the tumor, amelioration of symptoms, and a decrease of prostate-specific antigen in patient sera. However, with time, the majority of tumors recur in a more aggressive, castration-resistant (CR) phenotype. Currently, no effective treatment exists for this stage of the cancer, and patients ultimately succumb to metastatic disease. The androgen receptor (AR), which is a member of the nuclear hormone receptor superfamily of proteins, is the transcription factor that is responsible for mediating the effects of androgens upon target tissues, and it has been demonstrated to play a central role in the development and progression of prostate cancer. Despite CR tumor cells being able to continue to grow after hormonal therapy in which testosterone and dihydrotestosterone are markedly reduced, they still require the expression and activity of the AR. The AR can become transactivated in this low-androgen environment through a number of different mechanisms, including amplification and mutation of the receptor, cross talk with other signaling pathways, and altered regulation by coregulatory proteins. This review will summarizethe most current data regarding non-ligand-mediated activation of the AR in prostate cancer cells. Developing work in this field aims to more clearly elucidate the signals that drive AR activity independently of androgens in CR disease so that better therapeutic targets can be developed for patients with this stage of highly aggressive prostate carcinoma. (Molecular Endocrinology 25: 897-907, 2011).

UR - http://www.scopus.com/inward/record.url?scp=79957640371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957640371&partnerID=8YFLogxK

U2 - 10.1210/me.2010-0469

DO - 10.1210/me.2010-0469

M3 - Article

C2 - 21436259

AN - SCOPUS:79957640371

VL - 25

SP - 897

EP - 907

JO - Molecular Endocrinology

JF - Molecular Endocrinology

SN - 0888-8809

IS - 6

ER -